Conyers advises InnoCare Pharma Limited (“InnoCare”) on its pioneering red-chip listing on the Science and Technology Innovation Board of the Shanghai Stock Exchange, or SSE STAR Market in the PRC. We acted as special legal counsel in Cayman Islands and British Virgin Islands to InnoCare on its initial public offering of not more than 264,650,000 shares raising over RMB2.919 billion.

InnoCare was started from a group highly motivated scientists with a single focus, to provide patients around the world with modern, innovative drugs in the battle against cancers and autoimmune diseases.

Founded in 2015, InnoCare have had many distinguished accomplishments, including the submission of our first NDA for Orelabrutinib, a highly selective BTK inhibitor.

Partner Wynne Lau, Counsel Alexander Doyle, Associate Yvonne Lee and Charlie Chan and Legal Manager Sara Zou of Conyers’ Hong Kong office advised on the matter working alongside InnoCare’s PRC legal advisor, Fangda Partners, Beijing.

Stay current with our latest legal insights and subscribe today